Patch tests and hand eczema: retrospective study in 173 patients and literature review

Suzuki, Nathalie Mie; Hafner, Mariana de Figueiredo Silva; Lazzarini, Rosana; Duarte, Ida; Veasey, John Verrinder

doi:10.1016/j.abd.2022.02.007

Cited by 1 publication

(1 citation statement)

References 29 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors for CHE include frequent hand washing, exposure to wet conditions, concurrent atopic dermatitis, and occupational and not occupational exposures to various substances [ 1 , 4 ]. These substances can be found in cosmetics, jewelry, clothing, and medications and are often work-related [ 5 ]. Three main subcategories are recognized: irritant contact hand dermatitis, allergic contact dermatitis, and atopic hand dermatitis [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis

Tancredi,

Buononato,

Caccavale

et al. 2023

IJMS

View full text Add to dashboard Cite

Chronic hand eczema (CHE) is a common inflammatory skin condition that significantly impacts the quality of life. From work-related disabilities to social embarrassment, pain, and financial costs, the burden on society is substantial. Managing this condition presents challenges such as long-term treatment, poor patient compliance, therapy side effects, and economic feasibility. As a result, significant efforts have been made in this field in recent years. Specifically, the broader understanding of CHE pathogenesis has led to the development of new drugs, both topical and systemic. The aim of this narrative review is to summarize the current available data on hand eczema pathophysiology and explore the resulting developments in drugs for its treatment. A comprehensive search on PubMed and the other main scientific databases was conducted using keywords related to CHE and its pathogenesis. The most relevant pathways targeted by therapies include the JAK-STAT cascade, IL-4, and IL-13 axis, phosphodiesterase 4 enzyme, and chemo-attractant cytokines. In the near future, physicians will have a plethora of therapeutic alternatives. Consequently, they should be well-trained not only in how to use these alternatives but also how to combine these treatments to address the ongoing challenges related to efficacy, tolerability, and safety.

show abstract